Beyond PSA: The Role of Prostate Health Index (phi)

Background: Widespread use of prostate specific antigen (PSA) in screening procedures allowed early identification of an increasing number of prostate cancers (PCas), mainly including indolent cancer. Availability of different therapeutic strategies which have a very different impact on the patient&...

Full description

Bibliographic Details
Main Authors: Matteo Ferro, Ottavio De Cobelli, Giuseppe Lucarelli, Angelo Porreca, Gian Maria Busetto, Francesco Cantiello, Rocco Damiano, Riccardo Autorino, Gennaro Musi, Mihai Dorin Vartolomei, Matteo Muto, Daniela Terracciano
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:International Journal of Molecular Sciences
Subjects:
phi
Online Access:https://www.mdpi.com/1422-0067/21/4/1184
id doaj-5d379298136a48089129498def3d6cdb
record_format Article
spelling doaj-5d379298136a48089129498def3d6cdb2020-11-25T02:18:24ZengMDPI AGInternational Journal of Molecular Sciences1422-00672020-02-01214118410.3390/ijms21041184ijms21041184Beyond PSA: The Role of Prostate Health Index (phi)Matteo Ferro0Ottavio De Cobelli1Giuseppe Lucarelli2Angelo Porreca3Gian Maria Busetto4Francesco Cantiello5Rocco Damiano6Riccardo Autorino7Gennaro Musi8Mihai Dorin Vartolomei9Matteo Muto10Daniela Terracciano11Division of Urology, European Institute of Oncology, 20141 Milan, ItalyDivision of Urology, European Institute of Oncology, 20141 Milan, ItalyDepartment of Emergency and Organ Transplantation—Urology, Andrology and Kidney Transplantation Unit, University of Bari, 70124 Bari, ItalyDepartment of Urology, Abano Terme Hospital, 35031 Padua, ItalyDepartment of Urology, Sapienza University of Rome, 00185 Roma, ItalyDepartment of Urology, Magna Graecia University of Catanzaro, 88100 Catanzaro, ItalyDepartment of Urology, Magna Graecia University of Catanzaro, 88100 Catanzaro, ItalyDivision of Urology, VCU Health System, Richmond, VA 23219, USADivision of Urology, European Institute of Oncology, 20141 Milan, ItalyDepartment of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18–20, 1090 Vienna, AustriaRadiotherapy Unit, “S. G. Moscati” Hospital, 83100 Avellino, ItalyDepartment of Translational Medical Sciences, University of Naples “Federico II”, 8031 Naples, ItalyBackground: Widespread use of prostate specific antigen (PSA) in screening procedures allowed early identification of an increasing number of prostate cancers (PCas), mainly including indolent cancer. Availability of different therapeutic strategies which have a very different impact on the patient’s quality of life suggested a strong need for tools able to identify clinically significant cancer at diagnosis. Multi-parametric magnetic resonance showed very good performance in pre-biopsy diagnosis. However, it is an expensive tool and requires an experienced radiologist. In this context, a simple blood-based test is worth investigating. In this context, researchers focused their attention on the development of a laboratory test able to minimize overdiagnosis without losing the identification of aggressive tumors. Results: Recent literature data on PCa biomarkers revealed a clear tendency towards the use of panels of biomarkers or a combination of biomarkers and clinical variables. Phi, the 4Kscore, and Stockholm3 as circulating biomarkers and the Mi-prostate score, Exo DX Prostate, and Select MD-X as urinary biomarker-based tests have been developed. In this scenario, phi is worthy of attention as a noninvasive test significantly associated with aggressive PCa. Conclusions: Literature data showed that phi had good diagnostic performance to identify clinically significant (cs) PCa, suggesting that it could be a useful tool for personalized treatment decision-making. In this review, phi potentialities, limitations, and comparisons with other blood- and urinary-based tests were explored.https://www.mdpi.com/1422-0067/21/4/1184phiprostate canceroverdiagnosisclinical significance
collection DOAJ
language English
format Article
sources DOAJ
author Matteo Ferro
Ottavio De Cobelli
Giuseppe Lucarelli
Angelo Porreca
Gian Maria Busetto
Francesco Cantiello
Rocco Damiano
Riccardo Autorino
Gennaro Musi
Mihai Dorin Vartolomei
Matteo Muto
Daniela Terracciano
spellingShingle Matteo Ferro
Ottavio De Cobelli
Giuseppe Lucarelli
Angelo Porreca
Gian Maria Busetto
Francesco Cantiello
Rocco Damiano
Riccardo Autorino
Gennaro Musi
Mihai Dorin Vartolomei
Matteo Muto
Daniela Terracciano
Beyond PSA: The Role of Prostate Health Index (phi)
International Journal of Molecular Sciences
phi
prostate cancer
overdiagnosis
clinical significance
author_facet Matteo Ferro
Ottavio De Cobelli
Giuseppe Lucarelli
Angelo Porreca
Gian Maria Busetto
Francesco Cantiello
Rocco Damiano
Riccardo Autorino
Gennaro Musi
Mihai Dorin Vartolomei
Matteo Muto
Daniela Terracciano
author_sort Matteo Ferro
title Beyond PSA: The Role of Prostate Health Index (phi)
title_short Beyond PSA: The Role of Prostate Health Index (phi)
title_full Beyond PSA: The Role of Prostate Health Index (phi)
title_fullStr Beyond PSA: The Role of Prostate Health Index (phi)
title_full_unstemmed Beyond PSA: The Role of Prostate Health Index (phi)
title_sort beyond psa: the role of prostate health index (phi)
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2020-02-01
description Background: Widespread use of prostate specific antigen (PSA) in screening procedures allowed early identification of an increasing number of prostate cancers (PCas), mainly including indolent cancer. Availability of different therapeutic strategies which have a very different impact on the patient’s quality of life suggested a strong need for tools able to identify clinically significant cancer at diagnosis. Multi-parametric magnetic resonance showed very good performance in pre-biopsy diagnosis. However, it is an expensive tool and requires an experienced radiologist. In this context, a simple blood-based test is worth investigating. In this context, researchers focused their attention on the development of a laboratory test able to minimize overdiagnosis without losing the identification of aggressive tumors. Results: Recent literature data on PCa biomarkers revealed a clear tendency towards the use of panels of biomarkers or a combination of biomarkers and clinical variables. Phi, the 4Kscore, and Stockholm3 as circulating biomarkers and the Mi-prostate score, Exo DX Prostate, and Select MD-X as urinary biomarker-based tests have been developed. In this scenario, phi is worthy of attention as a noninvasive test significantly associated with aggressive PCa. Conclusions: Literature data showed that phi had good diagnostic performance to identify clinically significant (cs) PCa, suggesting that it could be a useful tool for personalized treatment decision-making. In this review, phi potentialities, limitations, and comparisons with other blood- and urinary-based tests were explored.
topic phi
prostate cancer
overdiagnosis
clinical significance
url https://www.mdpi.com/1422-0067/21/4/1184
work_keys_str_mv AT matteoferro beyondpsatheroleofprostatehealthindexphi
AT ottaviodecobelli beyondpsatheroleofprostatehealthindexphi
AT giuseppelucarelli beyondpsatheroleofprostatehealthindexphi
AT angeloporreca beyondpsatheroleofprostatehealthindexphi
AT gianmariabusetto beyondpsatheroleofprostatehealthindexphi
AT francescocantiello beyondpsatheroleofprostatehealthindexphi
AT roccodamiano beyondpsatheroleofprostatehealthindexphi
AT riccardoautorino beyondpsatheroleofprostatehealthindexphi
AT gennaromusi beyondpsatheroleofprostatehealthindexphi
AT mihaidorinvartolomei beyondpsatheroleofprostatehealthindexphi
AT matteomuto beyondpsatheroleofprostatehealthindexphi
AT danielaterracciano beyondpsatheroleofprostatehealthindexphi
_version_ 1724882478559133696